Designer Glycopeptides for Cytotoxic T Cell–based Elimination of Carcinomas
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Tumors express embryonic carbohydrate antigens called tumor-associated carbohydrate antigens (TACA). TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors, rendering a vaccination strategy applicable in a large population. Here we demonstrate that by using glycopeptides with high affinity for the major histocompatibility complex and glycosylated in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce anti-TACA CTL in vivo. In the current study we show that designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen (β-Gal-[1→3]-α-GalNAc-O-serine) are immunogenic in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro including a MUC1-expressing tumor. The fine specificity of the TF-specific CTL repertoire indicates that the TcR recognize the glycosylated amino acid residue together with TF in a conventional major histocompatibility complex class I–restricted fashion. These results have high potential for immunotherapy against a broad range of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haurum, J. S., Arsequell, G., Lellouch, A. C., Wong, S. Y., Dwek, R. A., McMichael, A. J., & Elliott, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.2.739 · Cited by 184
Haurum, J. S., Høier, I. B., Arsequell, G., Neisig, A., Valencia, G., Zeuthen, J., Neefjes, J., & Elliott, T. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.1.145 · Cited by 106
Abdel‐Motal, U. M., Berg, L., Rosén, A., Bengtsson, M., Thorpe, C. J., Kihlberg, J., Dahmén, J., Magnusson, G., Karlsson, K., & Jondal, M. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260307 · Cited by 85 · cited 1×
“One study that characterized the immunogenicity of designer glycopeptides modified a TcR contact(s) within a viral epitope described the induction of non-MHC class I–restricted CTL (47).”
Background
Cited by
Lakshminarayanan, V., Thompson, P., Wolfert, M. A., Buskas, T., Bradley, J. M., Pathangey, L. B., Madsen, C. S., Cohen, P. A., Gendler, S. J., & Boons, G.-J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115166109 · Cited by 301
Self-citationvan Vliet, S. J., van Liempt, E., Saeland, E., Aarnoudse, C. A., Appelmelk, B., Irimura, T., Geijtenbeek, T. B. H., Blixt, O., Alvarez, R., van Die, I., et al. (2005) · International Immunology · doi:10.1093/intimm/dxh246 · Cited by 238
Ryan, S. O., Vlad, A. M., Islam, K., Gariépy, J., & Finn, O. J. (2009) · bchm · doi:10.1515/bc.2009.070 · Cited by 60
“Tumor-associated glycopeptides deriv- ed from tumor MUC1 have been shown to be viable targets for T cells and anti-tumor immunity (Vlad et al., 2002; Xu et al., 2004; Ninkovic et al., 2009).”
Stergiou, N., Glaffig, M., Jonuleit, H., Schmitt, E., & Kunz, H. (2017) · ChemMedChem · doi:10.1002/cmdc.201700387 · Cited by 34
Antigen presentation of post‐translationally modified peptides in major histocompatibility complexes
de Wit, A. S., Bianchi, F., & van den Bogaart, G. (2025) · Immunology & Cell Biology · doi:10.1111/imcb.12839 · Cited by 12
Metadata
- Authors
- Xu, Y., Gendler, S. J., & Franco, A.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-03-01
- Volume
- 199
- Issue
- 5
- Pages
- 707-716
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2077949061
- Cited by
- 66
- References
- 3
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Designer Glycopeptides for Cytotoxic T Cell–based Elimination of Carcinomas. https://app.cochat.ai/papers/10.1084/jem.20031865
- The paper
- Xu, Y., Gendler, S. J., & Franco, A. (2004). Designer Glycopeptides for Cytotoxic T Cell–based Elimination of Carcinomas. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20031865
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.